IO-108

N/A

Report date: 2024/02/23 17:17:53

Base Information

Drug NameIO-108
Drug Alias NameIO-108
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsSolid tumoursLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesWorldMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesYiming Biomedical Technology (Hangzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmune-Onc Therapeutics IncF. Hoffmann-La Roche LtdYiming Biomedical Technology (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A